--2025/Q1-- / 6.300M--
--2024/Q4-- / 9.931M--
Nov 13, 20242024/Q340.901M / 20.489M--
Aug 12, 20242024/Q2128.231M / 44.762M--
May 15, 20242024/Q15.678M / 20.480M--
US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 0.665
- -0.010-1.44%
Trading Nov 20 13:28 ET
170.19MMarket Cap-3982P/E (TTM)
0.705High0.640Low3.70MVolume0.680Open0.675Pre Close2.45MTurnover2.33%Turnover RatioLossP/E (Static)255.88MShares2.05052wk High2.12P/B105.54MFloat Cap0.42152wk Low--Dividend TTM158.68MShs Float21.570Historical High--Div YieldTTM9.62%Amplitude0.420Historical Low0.662Avg Price1Lot Size
Adaptimmune Therapeutics Key Stats
Adaptimmune Therapeutics Q3 2024 Earnings Date
Currency：USDNov 13, 2024
| Estimate (YoY) | Actual (YoY) | Vs Estimate (% Chg) | |
| Revenue | 20.49M | 40.90M | +20.41M |
| Beat Est. | +179.94% | +458.83% | +99.63% |
| EPS | -0.08 | -0.06 | +0.02 |
| Beat Est. | -160.54% | +66.67% | +22.98% |
Analyst Rating
Nov 19, 2024
Adaptimmune Therapeutics Earnings Estimates
Revenue
EPS
EBIT
Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: USD
Actual
Estimate
Unlock Free Earnings Estimates
Open Account
Adaptimmune Therapeutics Earnings Reports
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
